Atlas Venture Fund Ix, L.P. has bought stock on 2 days since Apr 2018

Atlas Venture Fund IX, L.P. is a limited partnership investment fund managed by Atlas Venture, an early-stage venture capital firm focused on creating and investing in biotechnology companies, making it a corporate insider rather than an individual.( The fund, commonly referred to as Atlas IX, closed in 2013 with committed capital of approximately $265 million, raised to back early-stage life sciences and technology ventures, including significant positions such as its 10% ownership stake in Surface Oncology, Inc. (SURF).( As an SEC-reporting beneficial owner in SURF, Atlas Venture Fund IX, L.P. functions as a strategic financial investor rather than an operating company, exercising its influence primarily through board representation, capital support, and governance participation in its portfolio companies.(

Atlas Venture Fund IX, L.P. is part of the broader Atlas Venture platform, which has been creating and building biotechnology companies for over three decades from its headquarters in Cambridge, Massachusetts.( The Atlas organization is led by an experienced partnership that includes investors such as Bruce Booth, David Grayzel, Jason Rhodes, and Jean-François Formela, who oversee fund strategy, deal selection, and portfolio stewardship across vehicles including Fund IX.( Through Fund IX, Atlas pursued a seed-led, venture-creation model, often co-founding or incubating new therapeutics-focused biotech companies and partnering closely with entrepreneurs and strategic corporate limited partners such as Amgen Ventures and Novartis, which joined as corporate strategic partners at the closing of Atlas IX.(

Written by Perplexity from public sources.